Risk factors for postoperative nausea and vomiting after video-assisted thoracic surgery esophagectomy : a prospective cohort study
Video-assisted thoracic surgery esophagectomy (VATS-E) may increase the risk of postoperative nausea and vomiting (PONV) because it uses a high dosage of anesthesia through a long operative duration. However, no study has examined the risk factors for PONV after VATS-E. Therefore, we investigated the risk factors for PONV to support the appropriate risk management of PONV after VATS-E. This prospective cohort study included 155 patients who underwent VATS-E at the Showa University Hospital between April 1st, 2020 and November 30th, 2022. The primary outcome was the incidence of PONV within 24 h after surgery. Significant independent risk factors associated with the incidence of PONV were selected using multivariate analysis. The association between the number of risk factors for PONV and incidence of PONV was analyzed. One-hundred fifty-three patients were included in the analysis. The patients' median age was 67 years (range, 44-88), and 79.1% were male. PONV occurred in 35 (22.9%) patients. In the multivariate analysis, remifentanil dosage > 89.0 ng/kg/ min, albumin ≤ 3.5 g/dL, and eGFR < 60 mL/min/1.73 m 2 were independent significant risk factors for PONV. A significant association was observed between the incidence of and the number of risk factors for PONV (0 factor, 5.8%; 1 factor, 27.3%; ≥ 2 factors, 40.0%; p = 0.001). These three risk factors are useful indicators for selecting patients at high risk of developing PONV after VATS-E. In these patients, avoiding the development of PONV will be possible by performing appropriate risk management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Die Pharmazie - 79(2024), 1 vom: 29. Feb., Seite 17-23 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Muraoka, K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 07.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1691/ph.2024.3650 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369992091 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369992091 | ||
| 003 | DE-627 | ||
| 005 | 20240407232405.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1691/ph.2024.3650 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1368.xml |
| 035 | |a (DE-627)NLM369992091 | ||
| 035 | |a (NLM)38509627 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Muraoka, K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk factors for postoperative nausea and vomiting after video-assisted thoracic surgery esophagectomy |b a prospective cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 07.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Video-assisted thoracic surgery esophagectomy (VATS-E) may increase the risk of postoperative nausea and vomiting (PONV) because it uses a high dosage of anesthesia through a long operative duration. However, no study has examined the risk factors for PONV after VATS-E. Therefore, we investigated the risk factors for PONV to support the appropriate risk management of PONV after VATS-E. This prospective cohort study included 155 patients who underwent VATS-E at the Showa University Hospital between April 1st, 2020 and November 30th, 2022. The primary outcome was the incidence of PONV within 24 h after surgery. Significant independent risk factors associated with the incidence of PONV were selected using multivariate analysis. The association between the number of risk factors for PONV and incidence of PONV was analyzed. One-hundred fifty-three patients were included in the analysis. The patients' median age was 67 years (range, 44-88), and 79.1% were male. PONV occurred in 35 (22.9%) patients. In the multivariate analysis, remifentanil dosage > 89.0 ng/kg/ min, albumin ≤ 3.5 g/dL, and eGFR < 60 mL/min/1.73 m 2 were independent significant risk factors for PONV. A significant association was observed between the incidence of and the number of risk factors for PONV (0 factor, 5.8%; 1 factor, 27.3%; ≥ 2 factors, 40.0%; p = 0.001). These three risk factors are useful indicators for selecting patients at high risk of developing PONV after VATS-E. In these patients, avoiding the development of PONV will be possible by performing appropriate risk management | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Sato, M |e verfasserin |4 aut | |
| 700 | 1 | |a Yonezawa, R |e verfasserin |4 aut | |
| 700 | 1 | |a Kurihara, T |e verfasserin |4 aut | |
| 700 | 1 | |a Higuchi, S |e verfasserin |4 aut | |
| 700 | 1 | |a Kogo, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Die Pharmazie |d 1947 |g 79(2024), 1 vom: 29. Feb., Seite 17-23 |w (DE-627)NLM000009180 |x 0031-7144 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2024 |g number:1 |g day:29 |g month:02 |g pages:17-23 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1691/ph.2024.3650 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2024 |e 1 |b 29 |c 02 |h 17-23 | ||